文献速递淋巴瘤

儿童T细胞淋巴母细胞淋巴瘤的综合基因组分析揭示具有临床意义的候选标志物

Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance.
PubMed 文献 · Blood · 2021-01-01

本研究对儿童T细胞淋巴母细胞淋巴瘤(T-LBL)进行了首个纳入复发案例的全基因组整合分析,鉴定NOTCH1为驱动基因,KMT2D突变为预后标志物,突变型KMT2D患者复发累积发生率为47%±17%,野生型为14%±3%。

要点

  • NOTCH1是T-LBL的推定驱动基因,NOTCH/PI3K-AKT信号轴激活和细胞周期调控因子改变构成核心致癌程序。
  • KMT2D突变与复发风险显著升高相关:突变型复发累积发生率47%±17%,野生型14%±3%。
  • 正在进行的LBL 2018试验(NCT04043494)可前瞻性验证并微调T-LBL风险分层标准。

核心结论

  • KMT2D突变是T-LBL的预后标志物,与更高的复发累积发生率相关。
  • NOTCH1为T-LBL的推定驱动基因,NOTCH/PI3K-AKT信号轴激活及细胞周期调控因子改变构成核心致癌程序。

研究设计与样本

  • 首个纳入复发案例的全面、系统、全基因组整合分析。

主要发现

  • KMT2D突变患者复发累积发生率为47%±17%,野生型KMT2D患者为14%±3%。
  • 对KMT2D突变结构域的结构分析显示其对结构和功能后果有合理影响。

临床怎么用

  • KMT2D突变状态可用于T-LBL风险分层,识别高复发风险患者。
  • 正在进行的LBL 2018试验(NCT04043494)允许前瞻性验证并微调风险分层标准以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

T-cell lymphoblastic lymphoma (T-LBL) is a heterogeneous malignancy of lymphoblasts committed to T-cell lineage. The dismal outcomes (15%-30%) after T-LBL relapse warrant establishing risk-based treatment. To our knowledge, this study presents the first comprehensive, systematic, integrated, genome-wide analysis including relapsed cases that identifies molecular markers of prognostic relevance for T-LBL. NOTCH1 was identified as the putative driver for T-LBL. An activated NOTCH/PI3K-AKT signaling axis and alterations in cell cycle regulators constitute the core oncogenic program for T-LBL. Mutated KMT2D was identified as a prognostic marker. The cumulative incidence of relapse was 47% ± 17% in patients with KMT2D mutations, compared with 14% ± 3% in wild-type KMT2D. Structural analysis of the mutated domains of KMT2D revealed a plausible impact on structure and functional consequences. These findings provide new insights into the pathogenesis of T-LBL, including high translational potential. The ongoing LBL 2018 trial (www.clinicaltrials.gov #NCT04043494) allows for prospective validation and subsequent fine tuning of the stratification criteria for T-LBL risk groups to improve survival of pediatric patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Khanam T, Sandmann S, Seggewiss J, et al. Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood. 2021. PMID: 33152759. doi:10.1182/blood.2020005381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。